• Aviva (OTC: AIVAF) reported robust financial results, surpassing analyst expectations for both earnings and revenue, signaling strong operational performance.
• The company demonstrated significant growth with a 24% increase in operating profit and a 42% rise in gross written premiums, alongside a 7% increase in its interim dividend.
• Despite positive overall performance, Aviva adjusted its full-year outlook for its health business and saw a decrease in IFRS profit due to investment variances and restructuring costs.

Aviva (OTC: AIVAF), a leading multinational insurance provider and asset management company, offers a comprehensive range of products, including life insurance, general insurance, and fund management services. On August 14, 2026, Aviva announced robust financial results that surpassed analyst expectations for both earnings and revenue, signaling strong operational performance and a positive market outlook.

The company reported an earnings per share of $0.43, which is slightly above the consensus estimate. Earnings per share, or EPS, is a key profitability metric that shows how much profit a company makes for each share of its stock, reflecting strong shareholder value. This positive result is supported by a 24% increase in operating profit to £1.33 billion, as highlighted by Proactive Investors.

Aviva also surpassed revenue forecasts, reporting $39.83 billion against an expected $39.65 billion. This impressive revenue growth was primarily driven by its General Insurance division. Gross written premiums in the UK and Ireland climbed 42% to £5.91 billion. This figure was significantly boosted by the recent integration of Direct Line's business, enhancing Aviva's market share and strategic position.

Reflecting this strong performance, Aviva increased its interim dividend by 7% to 14.00 pence per share, underscoring its commitment to shareholder returns. Its IFRS return on equity, a key profitability metric that measures how well a company uses shareholder investments to generate profit, improved to 20.3%. Cash remittances, or internal cash transfers, also saw a large 47% increase to £1.50 billion, demonstrating robust cash flow management.

However, as highlighted by the WSJ, Aviva lowered its full-year outlook for its health business, indicating potential market challenges. IFRS profit for the period also decreased to £418.00 million from £819.00 million. This decline is attributed to negative investment variances along with costs related to business integration and restructuring efforts.